{"id":"https://openalex.org/W2397935232","doi":"https://doi.org/10.1158/1535-7163.targ-15-b174","title":"Abstract B174: Complementary activity of the vascular disruption agent BNC105 and the hypoxia-activated prodrug evofosfamide (TH-302) in suppressing the growth of preclinical renal and breast solid tumors","display_name":"Abstract B174: Complementary activity of the vascular disruption agent BNC105 and the hypoxia-activated prodrug evofosfamide (TH-302) in suppressing the growth of preclinical renal and breast solid tumors","alternate_titles":[],"publication_year":2015,"publication_date":"2015-12-01","ids":{"openalex":"https://openalex.org/W2397935232","doi":"https://doi.org/10.1158/1535-7163.targ-15-b174","mag":"2397935232"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.targ-15-b174","doi":"https://doi.org/10.1158/1535-7163.targ-15-b174","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-15-b174","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2397935232"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5085228897","display_name":"Tina C. Lavranos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102880","display_name":"Bionomics (Australia)","ror":"https://ror.org/01c6n0g60","country_code":"AU","type":"company","lineage":["https://openalex.org/I4210102880"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Tina C. Lavranos","raw_affiliation_strings":["1Bionomics Limited, Adelaide, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Bionomics Limited, Adelaide, Australia;","institution_ids":["https://openalex.org/I4210102880"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059432122","display_name":"Daniel J. Inglis","orcid":"https://orcid.org/0009-0007-8579-7846","observed_orcids":["https://orcid.org/0009-0007-8579-7846"]},"institutions":[{"id":"https://openalex.org/I4210102880","display_name":"Bionomics (Australia)","ror":"https://ror.org/01c6n0g60","country_code":"AU","type":"company","lineage":["https://openalex.org/I4210102880"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Daniel Inglis","raw_affiliation_strings":["1Bionomics Limited, Adelaide, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Bionomics Limited, Adelaide, Australia;","institution_ids":["https://openalex.org/I4210102880"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057692131","display_name":"Donna M. Beaumont","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102880","display_name":"Bionomics (Australia)","ror":"https://ror.org/01c6n0g60","country_code":"AU","type":"company","lineage":["https://openalex.org/I4210102880"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Donna Beaumont","raw_affiliation_strings":["1Bionomics Limited, Adelaide, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Bionomics Limited, Adelaide, Australia;","institution_ids":["https://openalex.org/I4210102880"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011262525","display_name":"Annabell F. Leske","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102880","display_name":"Bionomics (Australia)","ror":"https://ror.org/01c6n0g60","country_code":"AU","type":"company","lineage":["https://openalex.org/I4210102880"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Annabell F. Leske","raw_affiliation_strings":["1Bionomics Limited, Adelaide, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Bionomics Limited, Adelaide, Australia;","institution_ids":["https://openalex.org/I4210102880"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040811314","display_name":"Chloe Hawkins","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102880","display_name":"Bionomics (Australia)","ror":"https://ror.org/01c6n0g60","country_code":"AU","type":"company","lineage":["https://openalex.org/I4210102880"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Chloe Hawkins","raw_affiliation_strings":["1Bionomics Limited, Adelaide, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Bionomics Limited, Adelaide, Australia;","institution_ids":["https://openalex.org/I4210102880"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046953074","display_name":"Michaela A. Scherer","orcid":"https://orcid.org/0000-0001-7867-6498","observed_orcids":["https://orcid.org/0000-0001-7867-6498"]},"institutions":[{"id":"https://openalex.org/I4210102880","display_name":"Bionomics (Australia)","ror":"https://ror.org/01c6n0g60","country_code":"AU","type":"company","lineage":["https://openalex.org/I4210102880"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Michaela Scherer","raw_affiliation_strings":["1Bionomics Limited, Adelaide, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Bionomics Limited, Adelaide, Australia;","institution_ids":["https://openalex.org/I4210102880"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042870042","display_name":"Charles P. Hart","orcid":"https://orcid.org/0000-0003-4440-726X","observed_orcids":["https://orcid.org/0000-0003-4440-726X"]},"institutions":[{"id":"https://openalex.org/I4210106184","display_name":"Threshold Pharmaceuticals (United States)","ror":"https://ror.org/02bb3e325","country_code":"US","type":"company","lineage":["https://openalex.org/I4210106184"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles Hart","raw_affiliation_strings":["2Threshold Pharmaceuticals, San Fransisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Threshold Pharmaceuticals, San Fransisco, CA;","institution_ids":["https://openalex.org/I4210106184"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103985374","display_name":"Jessica D. Sun","orcid":"https://orcid.org/0000-0002-9844-9767","observed_orcids":["https://orcid.org/0000-0002-9844-9767"]},"institutions":[{"id":"https://openalex.org/I4210106184","display_name":"Threshold Pharmaceuticals (United States)","ror":"https://ror.org/02bb3e325","country_code":"US","type":"company","lineage":["https://openalex.org/I4210106184"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jessica Sun","raw_affiliation_strings":["2Threshold Pharmaceuticals, San Fransisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Threshold Pharmaceuticals, San Fransisco, CA;","institution_ids":["https://openalex.org/I4210106184"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008405453","display_name":"Brian Elenbaas","orcid":"https://orcid.org/0000-0002-7892-6028","observed_orcids":["https://orcid.org/0000-0002-7892-6028"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Brian Elenbaas","raw_affiliation_strings":["3Kura Oncology, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Kura Oncology, Boston, MA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5075832839","display_name":"Gabriel Kremmidiotis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210102880","display_name":"Bionomics (Australia)","ror":"https://ror.org/01c6n0g60","country_code":"AU","type":"company","lineage":["https://openalex.org/I4210102880"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Gabriel Kremmidiotis","raw_affiliation_strings":["1Bionomics Limited, Adelaide, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Bionomics Limited, Adelaide, Australia;","institution_ids":["https://openalex.org/I4210102880"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"14","issue":"12_Supplement_2","first_page":"B174","last_page":"B174"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.7221999764442444,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.7221999764442444,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10631","display_name":"Cancer, Hypoxia, and Metabolism","score":0.1550000011920929,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12356","display_name":"Bioactive Compounds and Antitumor Agents","score":0.014700000174343586,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/evofosfamide","display_name":"evofosfamide","score":0.9580000042915344},{"id":"https://openalex.org/keywords/hypoxia-activated-prodrug","display_name":"hypoxia-activated prodrug","score":0.9269999861717224},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7009999752044678},{"id":"https://openalex.org/keywords/kidney-cancer","display_name":"kidney cancer","score":0.6370000243186951},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.9879999756813049},{"id":"https://openalex.org/keywords/mda-mb-231-xenograft","display_name":"MDA-MB-231 xenograft","score":0.9940000176429749},{"id":"https://openalex.org/keywords/dose-range-finding","display_name":"dose range finding","score":0.6710000038146973},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5040000081062317},{"id":"https://openalex.org/keywords/tumor-hypoxia","display_name":"tumor hypoxia","score":0.7710000276565552},{"id":"https://openalex.org/keywords/nitroimidazoles","display_name":"nitroimidazoles","score":0.675000011920929}],"concepts":[{"id":"https://openalex.org/C108215921","wikidata":"https://www.wikidata.org/wiki/Q603741","display_name":"Prodrug","level":2,"score":0.8401859998703003},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6961053609848022},{"id":"https://openalex.org/C7836513","wikidata":"https://www.wikidata.org/wiki/Q1641506","display_name":"Hypoxia (environmental)","level":3,"score":0.5598539113998413},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.517082929611206},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.47866901755332947},{"id":"https://openalex.org/C2779081379","wikidata":"https://www.wikidata.org/wiki/Q7852677","display_name":"Tumor hypoxia","level":3,"score":0.4305148720741272},{"id":"https://openalex.org/C2778534260","wikidata":"https://www.wikidata.org/wiki/Q218706","display_name":"Erythropoietin","level":2,"score":0.4273381531238556},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3884182274341583},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.21569576859474182},{"id":"https://openalex.org/C540031477","wikidata":"https://www.wikidata.org/wiki/Q629","display_name":"Oxygen","level":2,"score":0.0},{"id":"https://openalex.org/C509974204","wikidata":"https://www.wikidata.org/wiki/Q180507","display_name":"Radiation therapy","level":2,"score":0.0},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.targ-15-b174","doi":"https://doi.org/10.1158/1535-7163.targ-15-b174","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-15-b174","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2148216490","https://openalex.org/W2075053538","https://openalex.org/W1970886784","https://openalex.org/W2206903933","https://openalex.org/W2228363212","https://openalex.org/W2807004674","https://openalex.org/W2737496940","https://openalex.org/W2325275602","https://openalex.org/W2802609269","https://openalex.org/W2234133053"],"abstract_inverted_index":{"Abstract":[0],"BNC105":[1,67,89,100,139,197,252,291,310,355,399,412,459,524],"is":[2,24,40,60,479],"a":[3,25,340,372,390],"vascular":[4,521],"disruption":[5,522],"agent":[6,34,523],"that":[7,95],"selectively":[8,49],"disrupts":[9],"tumor":[10,96,120,385,419,446],"blood":[11],"vessels":[12],"resulting":[13],"in":[14,74,103,153,155,236,245,318,393,483,531],"hypoxia":[15,97],"and":[16,45,68,90,134,193,202,244,260,275,292,300,309,329,369,439,489,525,538,552],"necrosis.":[17],"Evofosfamide":[18],"(previously":[19],"known":[20],"as":[21,339,421,423],"TH-302,":[22],"Evo)":[23],"nitroimidazole-triggered":[26],"prodrug":[27,528],"of":[28,88,107,113,148,176,231,287,315,321,371,377,409,427,442,458,519,535,545],"bromo-isophosphoramide":[29],"mustard":[30],"(Br-IPM),":[31],"an":[32],"alkylating":[33],"with":[35,350,361,397,444,460],"DNA":[36],"cross-linking":[37],"ability.":[38],"Evo":[39,52,69,114,141,161,185,222,261,293,308,357,401,416,461],"reduced":[41],"by":[42,99,326],"intracellular":[43],"reductases,":[44],"under":[46,56,63,271],"hypoxic":[47,64],"conditions":[48],"releases":[50],"Br-IPM.":[51],"has":[53],"little":[54],"activity":[55,518],"normoxic":[57],"conditions,":[58],"but":[59],"highly":[61],"cytotoxic":[62],"conditions.":[65],"Both":[66],"are":[70],"currently":[71,480],"being":[72,481],"evaluated":[73,213,482],"Phase":[75],"1-3":[76],"clinical":[77],"trials.":[78],"Our":[79],"studies":[80],"sought":[81],"to":[82,115,129,279,285,404,464],"establish":[83],"the":[84,119,131,138,146,177,215,232,237,246,272,319,327,354,362,398,424,437,445,456,477,520,526,533,546],"potential":[85],"therapeutic":[86],"combination":[87,154,206,233,341,358,402,408,457,478],"Evo.":[91,108,312],"It":[92],"was":[93,127,162,179,207,223,234,253,323,389,462],"reasoned":[94],"caused":[98],"will":[101],"result":[102],"increased":[104],"intratumoral":[105],"activation":[106],"A":[109,123,375],"greater":[110],"localized":[111],"conversion":[112],"Br-IPM":[116],"would":[117],"increase":[118],"kill":[121],"achieved.":[122],"dose":[124,132,186,211],"range-finding":[125],"study":[126,144],"conducted":[128],"define":[130],"level":[133],"administration":[135],"schedule":[136,364],"for":[137,182,281],"+":[140,311,356,400,413],"combination.":[142],"The":[143,205,228,313,407],"assessed":[145,235],"safety":[147],"administering":[149],"these":[150,334,474],"two":[151,335],"drugs":[152,178,216,336],"three":[156],"different":[157],"dosing":[158,288],"sequences":[159],"whereby":[160],"administered":[163,180,218,224,359],"1hr":[164,225],"prior":[165,284],"to,":[166],"immediately":[167],"following":[168],"(concurrently)":[169],"or":[170,220,257,353],"1":[171,299,368],"hr":[172],"after":[173],"BNC105.":[174,227],"Each":[175],"weekly":[181],"2":[183],"weeks.":[184],"levels":[187,212],"examined":[188],"were":[189,200,217,269,277,294,337,348,381],"50,":[190],"75,":[191],"100,":[192],"150":[194],"mg/kg,":[195],"and.":[196],"doses":[198],"investigated":[199],"10":[201,256],"16":[203,258,410],"mg/kg.":[204,264],"well-tolerated":[208],"at":[209,255,262],"all":[210],"when":[214,221,333],"concurrently":[219,296,360],"before":[226],"anti-tumor":[229],"efficacy":[230],"orthotopic":[238],"syngeneic":[239],"RENCA":[240,265],"renal":[241,537],"cancer":[242,249,267,488],"model":[243],"MDA-MB-231":[247,346,395],"breast":[248,539],"xenograft":[250],"model.":[251],"used":[254,338],"mg/kg":[259,411,415],"75":[263,414],"kidney":[266,273],"cells":[268],"inoculated":[270],"capsule":[274],"tumors":[276,316,396],"allowed":[278],"grow":[280],"11":[282],"days":[283],"commencement":[286],"(Day":[289,429],"1).":[290],"dosed":[295],"on":[297,366,384,473],"Days":[298,367],"8.":[301],"Treatment":[302],"groups":[303],"included:":[304],"vehicle":[305],"control;":[306],"BNC105;":[307],"growth":[314,386,420,447,534],"implanted":[317],"kidneys":[320],"mice":[322],"significantly":[324],"impeded":[325],"monotherapies":[328],"considerably":[330],"more":[331,466],"pronounced":[332],"treatment.":[342],"Mice":[343],"bearing":[344],"subcutaneous":[345],"xenografts":[347],"treated":[349],"BNC105,":[351],"Evo,":[352],"same":[363],"(dosing":[365],"8":[370,431],"21-day":[373],"cycle).":[374],"total":[376],"3":[378],"treatment":[379,428,443],"cycles":[380,441],"administered.":[382],"Based":[383,472],"inhibition,":[387],"there":[388],"clear":[391],"advantage":[392],"treating":[394],"compared":[403],"either":[405,469],"monotherapy.":[406],"substantially":[417],"inhibited":[418],"early":[422],"1st":[425],"cycle":[426],"1,":[430],"treatment).":[432],"This":[433],"effect":[434],"continued":[435],"through":[436],"2nd":[438],"3rd":[440],"curve":[448],"remaining":[449],"relatively":[450],"static.":[451],"In":[452],"both":[453],"models":[454,485],"tested":[455],"found":[463],"be":[465],"efficacious":[467],"than":[468],"therapy":[470],"alone.":[471],"encouraging":[475],"data":[476],"additional":[484],"including":[486],"pancreatic":[487],"soft":[490],"tissue":[491],"sarcoma.":[492],"Citation":[493],"Format:":[494],"Tina":[495],"C.":[496],"Lavranos,":[497],"Daniel":[498],"Inglis,":[499],"Donna":[500],"Beaumont,":[501],"Annabell":[502],"F.":[503],"Leske,":[504],"Chloe":[505],"Hawkins,":[506],"Michaela":[507],"Scherer,":[508],"Charles":[509],"Hart,":[510],"Jessica":[511],"Sun,":[512],"Brian":[513],"Elenbaas,":[514],"Gabriel":[515],"Kremmidiotis.":[516],"Complementary":[517],"hypoxia-activated":[527],"evofosfamide":[529],"(TH-302)":[530],"suppressing":[532],"preclinical":[536],"solid":[540],"tumors.":[541],"[abstract].":[542],"In:":[543],"Proceedings":[544],"AACR-NCI-EORTC":[547],"International":[548],"Conference:":[549],"Molecular":[550],"Targets":[551],"Cancer":[553,564],"Therapeutics;":[554],"2015":[555],"Nov":[556],"5-9;":[557],"Boston,":[558],"MA.":[559],"Philadelphia":[560],"(PA):":[561],"AACR;":[562],"Mol":[563],"Ther":[565],"2015;14(12":[566],"Suppl":[567],"2):Abstract":[568],"nr":[569],"B174.":[570]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2397935232","counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-11-14T11:04:58.165337","created_date":"2016-06-24T00:00:00"}
